|
Fig. 2 The thrombolytic effect of EPF3 on the thrombus model with platelet aggregation induced by arachidonic acid and anti-thrombotic effect of EPF3 on the thrombus model with vessel injury induced by FeCl3. (A) Photos of heart erythrocytes staining area of zebrafish (400×). (B) Integrated optical density of the heart erythrocytes staining area of zebrafish. (C) Thrombolytic effect. (D) Blood flow velocity of zebrafish thrombus model with platelet aggregation. (E) Thrombosis time of zebrafish. (F) Blood flow velocity of zebrafish thrombus model with vessel injury. Data were presented as mean ± standard deviation (n = 10 [A–D] and n = 8 [E and F]). ###P < 0.001, vs the Con group; *P < 0.05, **P < 0.01, and ***P < 0.001, vs the Mod group. ΔP < 0.05, vs the positive control (UK or ASA) groups. ASA: group administrated with 45 μg/mL aspirin; Con: control group; EH: group treated with 25 ng/tail EPF3; EL: group treated with 6.25 ng/tail EPF3; EM: group treated with 12.5 ng/tail EPF3; EPF3: a fibrinolysin monomer isolated and purified from Pheretima vulgaris Chen; Mod: model group; UK: group treated with 5 ng/tail urokinase.